Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer

Oncology

Volumn 77, Issue 3-4, 2009, Pages 244-253

  Chu, Edward ^a   Shi, Nianwen ^b   Wei, Wenhui ^c   Bendell, Johanna C ^d   Cartwright, Thomas ^e  

^a YALE CANCER CENTER   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e Ocala Oncology   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Chemotherapy; Colorectal cancer; Cost, cancer therapy; Pharmacoeconomics; Surgical resection; Treatment related complications

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURGERY; CATHETER INFECTION; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG COST; DRUG ERUPTION; DRUG FEVER; ESOPHAGITIS; FEMALE; GASTRITIS; HEADACHE; HUMAN; INSOMNIA; INTESTINE INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; PNEUMONIA; PNEUMOTHORAX; POLIOMYELITIS; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INFECTION; WEIGHT REDUCTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 69749121459     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236048     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Steele GD Jr: The National Cancer Data Base report on colorectal cancer. Cancer 1994; 74: 1979-1989.
3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-944.
4. Laurie JA, Moertel CG, Fleming TR, Wie - and HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J: Surgical adjuvant therapy of large-bowel carcino - ma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447-1456.
5. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
6. Xeloda (capecitabine) tablets [package insert]. Nutley, Roche Laboratories, 2006.
7. Twelves CJ: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006; 6: 278-287.
8. Twelves C, Scheithauer W, McKendrick J, Nowacki MP, Seitz JF, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J: Updated 5-year efficacy data from X-ACT trial of capecitabine vs. 5-FU/LV in stage III colon cancer and preliminary analysis of relationship between hand-foot syndrome and efficacy. Barcelona, World Congress on Gastrointestinal Cancer, June 25-28, 2008, poster O-O33.
9. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
10. Douillard JY, Tilleul P, Ychou M, Dufour P, Perrocheau G, Seitz JF, Maes P, Lafuma A, Husseini F: Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 2007; 72: 248-254.
11. Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Diaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP: Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-1129.
12. Schulman KL, Kohles J: Economic burden of metastatic bone disease in the US. Cancer 2007; 109: 2334-2342.
13. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A: Impact of varicella vaccination on health care utilization. JAMA 2005; 294: 797-802.
14. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
15. Kuehn BM: Better osteoporosis management a priority: impact predicted to soar with aging population. JAMA 2005; 293: 2453-2458.
16. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL: Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22: 3524-3530.
17. Chau I, Cunningham D: Adjuvant therapy in colon cancer - what, when and how? Ann Oncol 2006; 17: 1347-1359.
18. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD- 9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
19. VonKorff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
20. Baser O: Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006; 9: 377-385.
21. Baser O: Choosing propensity score matching over regression adjustment for causal inference: when, why and how it makes sense. J Med Econ 2007; 10: 379-391.
22. Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, Dubois RW: Outpatient cancer drug costs: changes, drivers, and the future. Cancer 2002; 94: 1142-1150.
23. Sipkoff M: Soaring price of cancer drugs leads plans to new approaches. Manag Care 2007; 16: 12-13.
24. Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J: Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006; 95: 1195-1201.
25. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW: Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Invest 2007; 27: 381-396.
26. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL: Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001; 6: 441-445.
27. Bennett CL, Calhoun EA: Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007; 12: 478-483.